Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy.

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Abstract Text:

Yurai Okaji,Nelson H Tsuno,Minoru Tanaka,Satomi Yoneyama,Mika Matsuhashi,Joji Kitayama,Shinsuke Saito,Yutaka Nagura,Takeshi Tsuchiya,Jun Yamada,Junichiro Tanaka,Naoyuki Yoshikawa,Takeshi Nishikawa,Yasutaka Shuno,Tomoki Todo,Nobuhito Saito,Koki Takahashi,Hirokazu Nagawa,

Vaccines targeting tumour angiogenesis were recently shown to inhibit tumour growth in animal models. However, there is still a lack of information about the clinical utility of anti-angiogenic vaccination. Therefore, here, we aimed to test the clinical effects of a vaccine using glutaraldehyde-fixed human umbilical vein endothelial cells (HUVECs). Six patients with recurrent malignant brain tumours and three patients with metastatic colorectal cancer received intradermal injections of 5x10(7) HUVECs/dose (in total 230 vaccinations). ELISA and flow cytometry revealed immunoglobulin response against HUVECs' membrane antigens. ELISPOT and chromium-release cytotoxicity assay revealed a specific cellular immune response against HUVECs, which were lysed in an effectors:targets ratio-dependent manner. Gadolinium-contrasted MRI showed partial or complete tumour responses in three malignant brain tumour patients. Except for a DTH-like skin reaction at the injection site, no adverse effect of vaccination could be observed. Our results suggest that the endothelial vaccine can overcome peripheral tolerance of self-angiogenic antigens in clinical settings, and therefore should be useful for adjuvant immunotherapy of cancer.

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Publishing Authors By Initials

Y Okaji,NH Tsuno,M Tanaka,S Yoneyama,M Matsuhashi,J Kitayama,S Saito,Y Nagura,T Tsuchiya,J Yamada,J Tanaka,N Yoshikawa,T Nishikawa,Y Shuno,T Todo,N Saito,K Takahashi,H Nagawa,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of cancer (Oxford, England : 1990

VOLUME: 44

Page Numbers: 383-90

Journal Abbreviation: Eur. J. Cancer

ISSN: 0959-8049

DAY: 3

MONTH: 12

YEAR: 2007

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9005373

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy.

AFFILIATION: Department of Transfusion Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; Department of Surgical Oncology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy Related Publications

• A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model.
• Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells.
• Basic fibroblast growth factor enema improves experimental colitis in rats.
• Chronic expanding hematoma in combination with a pseudoaneurysm: a case report.
• Clinical challenges and images in GI. Amoebic appendicitis.
• DNA methylation and sensitivity to antimetabolites in cancer cell lines.
• Early gastric cancer shows different associations with adipose tissue volume depending on histological type.
• Epigallocatechin gallate affects human dendritic cell differentiation and maturation.
• Good correlation between cerebral oxygenation measured using near infrared spectroscopy and stump pressure during carotid clamping.
• Heating and coagulation volume obtained with high-intensity focused ultrasound therapy: comparison of perflutren protein-type A microspheres and MRX-133 in rabbits.
• Hyperglycemia and hypertriglyceridemia may associate with the adenoma-carcinoma transition in colorectal epithelial cells.
• Isolated spontaneous dissection of the splanchnic arteries.
• Left-Sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right-sided ones.
• Leptin augments proliferation of breast cancer cells via transactivation of HER2.
• Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer-a study matched for tumor depth and pathology.
• Metastatic esophageal tumor from cecal carcinoma.
• Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma.
• Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy.
• Poorly differentiated colorectal adenocarcinomas show higher rates of microsatellite instability and promoter methylation of p16 and hMLH1: A study matched for T classification and tumor location.
• Preoperative radiation response evaluated by 18-fluorodeoxyglucose positron emission tomography predicts survival in locally advanced rectal cancer.
• Silencing of secreted frizzled-related protein genes in MSI colorectal carcinogenesis.